Loading...
•
Dec 31, 2024
STERIS Q3 2025 Earnings Report
STERIS reported its financial results for the third quarter of fiscal year 2025, showing an increase in total revenue and net income from continuing operations.
Key Takeaways
STERIS plc announced strong financial results for its fiscal 2025 third quarter, with total revenue from continuing operations increasing by 6% to $1.4 billion. Net income from continuing operations rose to $173.6 million, and adjusted EPS increased to $2.32. The company also updated its fiscal 2025 outlook, primarily due to shifts in foreign currency rates.
Total revenue from continuing operations increased 6% to $1.4 billion in Q3 fiscal 2025.
Constant currency organic revenue from continuing operations also grew by 6%.
As reported EPS from continuing operations increased to $1.75, while adjusted EPS rose to $2.32.
Healthcare revenue grew 7% to $976.0 million, driven by improvements in consumables and service revenue.
STERIS
STERIS
STERIS Revenue by Segment
STERIS Revenue by Geographic Location
Revenue by Segment
Healthcare Revenue
CapyFin.comAST Revenue
CapyFin.comLife Sciences Revenue
CapyFin.comRevenue by Geographic Location
Ireland Revenue
CapyFin.comUnited States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
For fiscal 2025, STERIS expects as reported revenue to increase approximately 6% and adjusted earnings per diluted share to be in the range of $9.05 to $9.15. Capital expenditures are anticipated to be around $360 million, with free cash flow expected to be approximately $700 million.
Positive Outlook
- Anticipated as reported revenue increase of approximately 6% for fiscal 2025.
- Constant currency organic revenue from continuing operations expected to be approximately 6%.
- Adjusted earnings per diluted share anticipated to be in the range of $9.05 to $9.15.
- Free cash flow expected to be approximately $700 million.
- Effective tax rate assumed to be approximately 23%.
Challenges Ahead
- Updated outlook reflects a significant shift in foreign currency based on forward rates through March 31, 2025, which is expected to be unfavorable to revenue.
- Lower than anticipated revenue for capital equipment in the Healthcare segment.
- Approximately ten cent negative impact on adjusted EPS from currency.
- Outlook does not reflect any potential impact from new tariffs.
- Capital expenditures are anticipated to be approximately $360 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income